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The clinical use of chemotherapeutic drugs is greatly hampered by a combination of 
severe side effects on healthy organs and low accumulation in the tumor tissue. Although 
entrapment in stable liposomes has long been known to increase tumor accumulation while 
protecting the drug in circulation, drug release after accumulation is generally low, leading to 
poor bioavailability and consequently poor therapeutic effect [1,2]. This essentially underlines 
the paradoxical problem of how to simultaneously maintain liposome stability in circulation 
and obtain efficient drug release at the tumor site.  
One compelling solution is utilizing an endogenous trigger mechanism that relies on a 
difference between microenvironment of the tumor and the healthy tissue. Secretory 
phospholipase A2 (sPLA2) is reported to be expressed at an elevated level in many tumor 
types [3,4]. This enzyme catalyzes the hydrolysis of phospholipids, producing equimolar 
concentrations of lysolipids and free fatty acids [5]. For liposomes this has a dual effect: 
rupture of the membrane, causing site specific release of encapsulated drug, and production of 
potentially lytic agents that can permeabilize the cell membrane mediating more efficient 
drug uptake [6,7] (Figure 1).  
 	
	
	
	
	
	
	
	
Figure	1:	Conceptual illustration. Liposome encapsulated oxaliplatin will circulate until it 
encounters the fenestrated capillaries in the tumor tissue, where it extravasates. Here it 
encounters an elevated level of secretory phospholipase A2 (sPLA2), which hydrolyses the 
phosphoglycerolipids, causing release of the drug. In addition the hydrolysis products, lyso-
lipids and free fatty acids, may act as permeability enhancers, thus further contributing to 
drug transport across the cellular membrane.   
The concept of sPLA2 responsive liposomes has been widely studied in cell free 
systems and in vitro [7–10]. Yet very few studies have reported on in vivo data [11,12], and 
only one formulation with this concept has made it to clinical trials [13]. Here we present the 
rational design of liposomes optimized for secretory phospholipase A2 (sPLA2) triggered drug 
release, and test their utility in vitro and in vivo.  
Studies with MALDI-TOF MS revealed an sPLA2 dependent hydrolysis of liposomal 
phospholipids, demonstrating that these nanoparticles are truly enzyme sensitive. Further, in 
vitro release studies with ICP-MS disclosed enzyme dependent release of the liposome 
encapsulated drug oxaliplatin, signifying their potential for controlled release of cancer drugs.   
Treatment of two different cancer cell lines with liposomal oxaliplatin showed 
efficient growth inhibition compared to that of clinically used stealth liposomes. In the 
presence of excess sPLA2 the liposomal oxaliplatin was also superior to free oxaliplatin, 
suggesting a boosting therapeutic effect by the lysis products, possibly due to enhanced 
cellular uptake over a slightly permeabilized membrane. Empty liposomes induced a small 
sPLA2 dependent growth inhibition, but did not demonstrate a severe cell death profile, 
implying that these liposomes should be inactive, and thus safe, in circulation, where the 
sPLA2 level is low.  
Although the in vitro results were promising, real clinical potential can only be 
disclosed by in vivo evaluation. For this purpose we utilized the human, sPLA2 secreting, 
mammary carcinoma cell line MT-3, transplanted onto female nude NMRI mice. Mice 
received 10 mg/kg oxaliplatin, the liposomal equivalent or isotonic glucose solution by tail 
vein injection. Three days after the first treatment all mice having received liposomal 
oxaliplatin were euthanized due to severe systemic toxicity (excessive weight loss, 
dehydration and subcutaneous bleedings). Mice having received control compounds showed 
no signs of discomfort. 
Although speculated to be related to the phospholipid hydrolysis products, the exact 
mechanistic cause of the systemic toxicity is not yet known. Preliminary histopathology 
studies of liver sections displayed acute multifocal necrosis of hepatocytes with a collapse of 
hepatic sinusoids and hydropical injury to the cell nuclei, which is believed to be the 
biological cause of the observed toxicity. Consequently, the in vivo study was not repeated.  
The present study demonstrates that great caution should be implemented when 
utilizing sPLA2 sensitive liposomes. Even though many have shown potential in vitro, the real 
utility can only be disclosed in vivo. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2: Effect of sPLA2 sensitive liposomes. A) In vitro antiproliferative effect of free 
oxaliplatin (OxPt) (closed circles), empty (open diamonds) or OxPt loaded (open circles) 
sPLA2 sensitive liposomes (SSLs) or OxPt loaded Stealth liposomes (closed diamonds). Cell 
survival was evaluated by MTS staining. Values are mean of triplicates ± SD. All values are 
normalized to non-treated cells.  The data is representative of minimum three separate 
experiments. B) In vivo evaluation. Mouse treated with oxaliplatin loaded sPLA2 sensitive 
liposomes was euthanized 3 days after first treatment due to excessive weight loss, 
dehydration and subcutaneous bleedings.  
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